Nkarta to Participate in March Investor Conferences
Friday, February 27, 2026 1 min read
Key Takeaway: Nkarta, Inc. announced its participation in two upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference, where Nkarta will host fireside chats. Both events will be available via webcast, enhancing accessibility for investors.
Price reaction · baseline $2.62 (2026-02-26 close) · hit pre-market · clean, no other NKTX news in the window
day 0 close · peak
+3.1%
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is actively engaging with investors through conferences.
The company is advancing innovative NK cell therapies.
Webcasts of the events will be available for broader access.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:
March 2, 2026TD Cowen 46th Annual Health Care ConferenceBoston, MA9:10 a.m. EST – fireside chatMarch 10, 2026Leerink Global Healthcare ConferenceMiami, FL10:40 a.m. EDT – fireside chatA simultaneous webcast of both events will be available on theInvestors sectionof Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website atwww.nkartatx.com.